Performance of a multi-cancer early detection test (MCED) for detecting small hepatocellular carcinoma (HCC) in a screening population.

G Gangchao Xu (Department of General Surgery, Huidong People's Hospital, Huizhou, China) Q Qiang Liu S Shutong Wang (Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China) W Wentao Liu (State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science) S Shiting Feng (Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China) W Weifeng Zhu T Tao Zhou (College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China.) Q Qiumei Zhuang (Health Management Center, Huidong People's Hospital, Huizhou, China) H Hui Yu (Hefei National Laboratory for Physical Sciences at the Microscale and Department of Chemistry) Y Yue Wang M Min Li J Jie Yang C Cuicui Wang J Jing Liu B Baoliang Zhu (Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China) X Xiaohui Wu (Key Laboratory of Functional Polymer Materials of Ministry of Education, Institute of Polymer Chemistry, State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, Haihe Laboratory of Sustainable Chemical Transformations, College of Chemistry) R Ruifeng Jing (Guangzhou National Laboratory, Guangzhou, China) Q Qinfeng Wen (Department of Medical Affairs, Huidong People's Hospital, Huizhou, China) D Dongdong Yu

Abstract

4168 Background: Early diagnosis of small HCC (defined as single nodule ≤ 3 cm) is crucial, as it represents the optimal window for curative treatments. Abdominal ultrasound with alpha-fetoprotein (AFP) is recommended for HCC surveillance in high-risk population. However, traditional modality detects only ~63% of small HCC, resulting in most HCC being diagnosed at advanced stages. Genie-Seq, a cfDNA-based MCED assay, covers 5 high-mortality cancers including HCC. Here, we report preliminary results evaluating the performance of Genie-Seq for small HCC in an asymptomatic screening population. Methods: Participants aged 40-74 years with no clinical suspicion of cancer were enrolled in a prospective, interventional study. All participants underwent Genie-Seq testing and standard-of-care (SOC) screenings according to the China Guidelines for Cancer Screening, including abdominal ultrasound and AFP. Genie-Seq detects cancer signals and localizes tissue-of-origin (TOO) simultaneously. Further HCC-focused diagnostic workup was performed per physician's discretion if: 1) suspicious findings on HCC screening, or 2) positive MCED results with liver as the top-predicted TOO. Diagnostic outcomes were reviewed for cancer status, TOO prediction accuracy, and stage. Results: As of December 2025, 1210 participants completed MCED testing and HCC screening. Nine participants were suspected of HCC and underwent further evaluation, with definitive diagnosis achieved in 7. Of these, 4 were confirmed as HCC (3 small HCCs, 1 stage II), 1 had synchronous gastric and colorectal cancers, and 2 had benign hepatic lesions. Genie-Seq identified all HCC cases with 100% TOO prediction accuracy, including 2 that were missed or initially misdiagnosed by traditional imaging. Patient 885 was exclusively identified by MCED, as no nodule was detected by ultrasound. Patient 888 had atypical features on contrast-enhanced CT/Gd-EOB-DTPA MRI (initial suspicion of inflammatory pseudotumor), and Genie-Seq positivity prompted contrast-enhanced ultrasound, leading to definitive diagnosis of small HCC. Conclusions: Genie-Seq exhibits excellent performance for small HCC detection in screening population, supporting it as a complementary tool to conventional preventive care and potentially improving curable HCC detection. Diagnostic outcomes of participants achieved diagnostic resolution. Participants Suspicious Lesions Detected by Ultrasound AFP (ng/ml) [1] MCED Results Diagnosis Tumor Stage (AJCC) 0108 Yes 2.96 Negative Hepatic cysts 0572 Yes 4.25 Negative Hepatic cavernous hemangioma 0640 No 2.6 Positive Multiple primary cancers Gastric cancer: IIB Colorectal cancer: I 0723 Yes 58.55 Positive HCC II 0885 No 8.16 Positive HCC IA 0888 Yes 42.53 Positive HCC IB 0971 Yes 9.11 Positive HCC IA [1] AFP levels of < 7 ng/mL were defined as normal.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
Pages 4168-4168
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (19)

G

Gangchao Xu

Department of General Surgery, Huidong People's Hospital, Huizhou, China

Q

Qiang Liu

S

Shutong Wang

Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

W

Wentao Liu

State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science

S

Shiting Feng

Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

W

Weifeng Zhu

T

Tao Zhou

College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China.

Q

Qiumei Zhuang

Health Management Center, Huidong People's Hospital, Huizhou, China

H

Hui Yu

Hefei National Laboratory for Physical Sciences at the Microscale and Department of Chemistry

Y

Yue Wang

M

Min Li

J

Jie Yang

C

Cuicui Wang

J

Jing Liu

B

Baoliang Zhu

Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China

X

Xiaohui Wu

Key Laboratory of Functional Polymer Materials of Ministry of Education, Institute of Polymer Chemistry, State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, Haihe Laboratory of Sustainable Chemical Transformations, College of Chemistry

R

Ruifeng Jing

Guangzhou National Laboratory, Guangzhou, China

Q

Qinfeng Wen

Department of Medical Affairs, Huidong People's Hospital, Huizhou, China

D

Dongdong Yu